Search

Author/Creator Rosati, Claudio

2. Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study. Issue 9 (September 2021)

Authors:
Calabrò, Luana; Rossi, Giulia; Morra, Aldo; Rosati, Claudio; Cutaia, Ornella; Daffinà, Maria Grazia; Altomonte, Maresa; Di Giacomo, Anna Maria; Casula, Milena; Fazio, Carolina; Palmieri, Giuseppe; Giannarelli, Diana; Covre, Alessia; Maio, Michele
Journal:
Lancet
Issue:
Volume 9:Issue 9(2021)
Page Start:
969
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search